- Home
- CVR vs IMNN Comparison
CVR vs IMNN Comparison
Compare CVR & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVR | IMNN |
|---|---|---|
| Founded | 1920 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 11.0M |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CVR | IMNN |
|---|---|---|
| Price | $10.24 | $3.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.9K | ★ 58.9K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,890,260.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.35 | N/A |
| 52 Week Low | $8.15 | $0.37 |
| 52 Week High | $15.00 | $9.32 |
Technical Indicators
Market Signals| Indicator | CVR | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 31.81 | 58.33 |
| Support Level | $8.78 | $3.03 |
| Resistance Level | $14.61 | $3.61 |
| Average True Range (ATR) | 0.60 | 0.24 |
| MACD | -0.39 | 0.03 |
| Stochastic Oscillator | 14.77 | 97.22 |
Price Performance
Historical ComparisonAbout CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).